Recent Updates
Recently added Catalysts

recombinant interferon alfa

Phase 2

Gastrointestinal Carcinoid Tumor | Monoclonal antibody | Oncology |Atlantic International Corp.|Last Updated: May 15, 2013

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment -
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00002470Fluorouracil Plus Interferon Alfa in Treating Patients With Advanced Metastatic Carcinoid TumorsPHASE2 COMPLETED - — — Sep 1, 1990Jan 1, 2004May 15, 20131 United States
Unlock Drug Trial Details
Study Design & Arms
PurposeTREATMENT
Interventions
NameTypeDescription
recombinant interferon alfaBIOLOGICAL -
fluorouracilDRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites1

DISEASE CHARACTERISTICS: * Histologically proven carcinoid tumor with radiologically confirmed metastatic disease * Recurrence after surgery or radiotherapy allowed * Must meet at least 1 of the following conditions: * Symptomatic carcinoid syndrome not controlled * Other systemic symptoms (e....

Countries:United States
Unlock Eligibility Criteria